Public Sector Pension Investment Board purchased a new position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 774,309 shares of the company's stock, valued at approximately $20,326,000. Public Sector Pension Investment Board owned approximately 0.62% of Arcutis Biotherapeutics at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also bought and sold shares of ARQT. Bank of America Corp DE lifted its holdings in Arcutis Biotherapeutics by 32.7% in the 1st quarter. Bank of America Corp DE now owns 2,221,289 shares of the company's stock worth $52,334,000 after purchasing an additional 547,835 shares during the last quarter. Tejara Capital Ltd acquired a new position in Arcutis Biotherapeutics during the second quarter valued at approximately $2,965,000. Sei Investments Co. grew its holdings in Arcutis Biotherapeutics by 97.7% during the first quarter. Sei Investments Co. now owns 206,141 shares of the company's stock valued at $4,857,000 after purchasing an additional 101,855 shares during the last quarter. Legal & General Group Plc acquired a new position in Arcutis Biotherapeutics during the second quarter valued at approximately $2,643,000. Finally, Jupiter Topco LLC bought a new position in shares of Arcutis Biotherapeutics in the second quarter valued at approximately $36,989,000.
Insider Activity
In other news, Director Howard G. Welgus sold 4,728 shares of the business's stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $26.93, for a total transaction of $127,325.04. Following the transaction, the director owned 35,207 shares in the company, valued at approximately $948,124.51. The trade was a 11.84% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Masaru Matsuda sold 40,000 shares of the company's stock in a transaction dated Wednesday, November 4th. The shares were sold at an average price of $34.32, for a total transaction of $1,372,800.00. Following the transaction, the executive vice president directly owned 111,289 shares of the company's stock, valued at $3,819,438.48. This represents a 26.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders sold 103,130 shares of company stock worth $3,006,478. Corporate insiders own 9.40% of the company's stock.
Wall Street Analysts Forecast Growth
A number of analysts have recently weighed in on ARQT shares. TD Cowen boosted their price objective on shares of Arcutis Biotherapeutics from $35.00 to $40.00 and gave the stock a "buy" rating in a research note on Thursday, November 5th. Cantor Fitzgerald initiated coverage on shares of Arcutis Biotherapeutics in a research note on Thursday, October 15th. They issued an "overweight" rating and a $48.00 target price on the stock. Jefferies Financial Group reiterated a "buy" rating and issued a $39.00 target price on shares of Arcutis Biotherapeutics in a report on Thursday, October 8th. Morgan Stanley boosted their target price on shares of Arcutis Biotherapeutics from $34.00 to $38.00 and gave the stock an "overweight" rating in a research report on Thursday, August 6th. Finally, Guggenheim upped their price target on shares of Arcutis Biotherapeutics from $38.00 to $44.00 and gave the company a "buy" rating in a report on Monday, October 19th. Eight equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $39.75.
Get Our Latest Analysis on ARQT
Arcutis Biotherapeutics Stock Down 3.0%
Shares of ARQT stock opened at $26.36 on Friday. Arcutis Biotherapeutics, Inc. has a 12 month low of $19.30 and a 12 month high of $34.80. The company has a quick ratio of 2.66, a current ratio of 2.92 and a debt-to-equity ratio of 0.42. The firm has a market cap of $3.33 billion, a PE ratio of 125.52 and a beta of 1.66. The stock has a 50 day moving average of $27.86 and a 200-day moving average of $25.44.
Arcutis Biotherapeutics (NASDAQ:ARQT - Get Free Report) last announced its quarterly earnings data on Wednesday, November 4th. The company reported $0.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.18 by ($0.12). Arcutis Biotherapeutics had a return on equity of 14.18% and a net margin of 5.88%. The company had revenue of $143.92 million during the quarter, compared to analyst estimates of $142.59 million. On average, equities analysts predict that Arcutis Biotherapeutics, Inc. will post 0.28 EPS for the current year.
Arcutis Biotherapeutics Profile
(
Free Report)
Arcutis Biotherapeutics is a biopharmaceutical company focused on developing and commercializing treatments for inflammatory skin diseases. Founded in 2016, the company is headquartered in Westlake Village, California. Arcutis primarily serves the U.S. market and continues to develop medicines for dermatologic conditions. Its leadership is headed by President and Chief Executive Officer Frank Watanabe.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Arcutis Biotherapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arcutis Biotherapeutics wasn't on the list.
While Arcutis Biotherapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.